L-Rotator Biotech completed its pre-A financing and continued to increase its investment in the CGT field

At the beginning of the new year, Vientiane renewed, and Suzhou L-Star Biotechnology Co., Ltd. (hereinafter referred to as "L-Star Biotechnology") completed the second financing within one year. The financing, which is exclusively invested by Matrix Partners Ventures, will be used to expand GMP manufacturing for cell gene therapy products and upgrade and expand the safety testing and evaluation platform.

L-Star Biotech was established in March 2022 and has received angel round investment from Jifeng Capital and Mint Angel Fund. The whole team has been deeply engaged in the field of drug quality testing and production for more than ten years. The company was founded with a determination to serve the cell and gene therapy (CGT) industry, which is in the midst of explosive growth, with a particular focus on securing and servicing the rapid pipeline of many emerging CGT companies. L-Tek has developed a complete set of cost-effective and rigorous solutions for different stages of CGT's R&D period, pre-clinical to clinical trial stage.

Dr. Xin Wu, Founder and CEO of Leftox, said, "We would like to thank Matrix Partners for their recognition and support of L-Rotos, which also reflects the common optimism of Matrix Partners and L-Tex for the prospects of cell and gene therapy. Cell therapy, gene therapy and nucleic acid drugs represented by mRNA drugs have opened up the third battlefield for human beings to overcome diseases, although the past year has been a harsh environment, but the field of cell gene therapy has still achieved world-renowned results, and we also hope that new investment and development can provide more ammunition and guarantee for this battle. ”

Sun Linghao, Managing Director of Matrix Partners Ventures, said, "We continue to be optimistic about the long-term development of cell and nucleic acid drugs in China, and invest in a number of potential companies in all aspects of the industry chain. The L-Star team has been deeply engaged in the industry for many years and has rich experience in the R&D and production of mRNA drugs and other fields. With the rapid development of the industry, we look forward to accompanying the company for a long time and becoming a high-quality brand in the field of cell nucleic acid drug development and production outsourcing. ”

About Matrix Partners

Founded in 2008, Matrix Partners is a leading venture capital institution in the industry that has long focused on early-stage and early-growth investment, focusing on investment in new technologies, hard technologies, industrial digitalization, healthcare, cutting-edge technologies, and new consumption. At present, it has invested in more than 700 enterprises, including Xpeng Motors, Li Auto, Jimi Technology, Rongbai Technology, Haichen Energy Storage, PingCAP, Beisen, Xinchi Technology, Taimei Medical Technology, Fauvism, Zihi Pot, Jane Ai, Magga Robot, etc.